Brenda Reynolds, who holds a degree in Toxicology, and is an IOD Chartered Director, was a founder and the Chief Operating Officer of Convergence Pharmaceuticals. Prior to that, Reynolds was COO of PowderMed Ltd.; Vice President of Portfolio & Programme Management at PowderJect Pharmaceuticals plc. She has also held a number of senior positions across the healthcare sector including roles at Pfizer, Scotia Holdings PLC, G D Searle.  Currently, Reynolds ist Director of iQur and BQR Consulting Ltd. 

In addition to the new appointments, Kevin Cox and Tim Watts were also re-elected for a term of three years. Standing down from the board after having completed their terms of office are Edward Hodgkin of Syncona, Stephen Taylor, retired from Fujifilm Diosynth Biotechnologies, and Ian Tomlinson of the Stevenage Bioscience Catalyst and Apollo Therapeutics.